Investment Thesis
Boundless Bio is a pre-revenue biopharmaceutical company with strong balance sheet metrics but facing critical near-term cash constraints. With -15M quarterly operating cash flow against only 17.5M cash reserves, the company has approximately one quarter of runway before requiring additional financing. While zero debt and 86.4M in equity are positives, the combination of zero revenue, unsustainable cash burn, and inherent biotech development risk creates an unfavorable risk-reward profile for most investors.
Strengths
- Strong balance sheet with 86.4M stockholders' equity and zero long-term debt
- Excellent liquidity position (9.87x current ratio) eliminates near-term solvency risk
- Minimal capital expenditure (8K) indicates lean operations appropriate for early-stage biotech development
Risks
- Critical cash runway: Only 17.5M cash against 15M quarterly operating burn (approximately one quarter of operations)
- Pre-revenue business model: Zero revenue; entire business thesis depends entirely on unproven pipeline execution
- High biotech development risk: Unfavorable clinical outcomes, regulatory setbacks, or failure to achieve milestones could be fatal
Key Metrics to Watch
- Quarterly cash burn rate and runway remaining before next financing need
- Clinical trial progress, patient enrollment, and regulatory milestone announcements
- Capital raise announcements and terms of financing to determine dilution impact
Financial Metrics
Revenue
N/A
Net Income
-13.6M
EPS (Diluted)
$-0.60
Free Cash Flow
-15.0M
Total Assets
141.0M
Cash
17.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-15.7%
ROA
-9.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
9.87x
Quick Ratio
9.87x
Debt/Equity
0.00x
Debt/Assets
38.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:19:34.468977 |
Data as of: 2026-03-31 |
Powered by Claude AI